- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00552617
A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)
A Multi-Center, Randomized, Open-Label, Prospective Bridging, Parallel Dose-Finding Trial Comparing Efficacy, Safety and Pharmacokinetics of 4 Doses of Org 25969 and Placebo Administered at Reappearance of T2 After Rocuronium or Vecuronium in Japanese and Caucasian Subjects. Part B: Caucasian Subjects
연구 개요
상세 설명
연구 유형
등록 (실제)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Is of American Society of Anesthesiologists (ASA) class 1 - 3;
- Is at least 20 years but under 65 years of age;
- Caucasian participants;
- Is scheduled for elective surgery requiring muscle relaxation in supine position and under sevoflurane anesthesia with an anticipated duration of about 1.5-3 hours;
- Has given written informed consent.
Exclusion criteria:
- Participants in whom a difficult intubation because of anatomical malformations was expected;
- Is known or suspected to have neuromuscular disorders impairing neuromuscular blocking (NMB) and/or significant renal dysfunction (for example a creatinine level > 1.6 mg/dl) and/or severe hepatic dysfunction.
- Is known or suspected to have a (family) history of malignant hyperthermia;
- Is known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;
- Is receiving medication expected to interfere with the rocuronium or vecuronium given in this trial, based on the dose and time of administration;
- Females who were pregnant;
- Females of childbearing potential not using birth control or using only oral contraception as birth control;
- Was breast-feeding;
- Has already participated in P05971, or in another trial with sugammadex;
- Has participated in another clinical trial, not preapproved by the Sponsor, within 6 months of entering into P05971.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
위약 비교기: 로쿠로늄 + 위약
마취 유도 후 로쿠로늄 0.9 mg/kg의 삽관 용량을 정맥내(IV) 투여한 후 0.1-0.2의 유지 용량을 투여했습니다.
필요한 경우 mg/kg 로쿠로늄 IV.
T2가 다시 나타날 때 위약의 단일 용량을 IV로 투여했습니다.
|
After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of Placebo IV was administered After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. |
실험적: Rocuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2
mg/kg rocuronium IV if necessary.
At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
|
실험적: Rocuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2
mg/kg rocuronium IV if necessary.
At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
|
실험적: Rocuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2
mg/kg rocuronium IV if necessary.
At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
|
실험적: Rocuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2
mg/kg rocuronium IV if necessary.
At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
|
위약 비교기: Vecuronium + Placebo
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03
mg/kg vecuronium IV if necessary.
At reappearance of T2 a single dose of placebo was administered IV.
|
After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of Placebo IV was administered
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV.
Maintenance doses of 0.02-0.03
mg/kg vecuronium IV could be administered if necessary.
|
실험적: Vecuronium + 0.5 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03
mg/kg vecuronium IV if necessary.
At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV.
Maintenance doses of 0.02-0.03
mg/kg vecuronium IV could be administered if necessary.
|
실험적: Vecuronium + 1.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03
mg/kg vecuronium IV if necessary.
At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV.
Maintenance doses of 0.02-0.03
mg/kg vecuronium IV could be administered if necessary.
|
실험적: Vecuronium + 2.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03
mg/kg vecuronium IV if necessary.
At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV.
Maintenance doses of 0.02-0.03
mg/kg vecuronium IV could be administered if necessary.
|
실험적: Vecuronium + 4.0 mg/kg Sugammadex
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03
mg/kg vecuronium IV if necessary.
At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.
|
After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered
다른 이름들:
After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV.
Maintenance doses of 0.02-0.03
mg/kg vecuronium IV could be administered if necessary.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Sugammadex 또는 위약 투여 시작부터 네 번째 연축/첫 번째 연축(T4/T1) 비율이 0.9로 회복되기까지의 시간
기간: 1일차: 슈가마덱스 또는 위약 투여 시작부터 T4/T1 비율이 0.9로 회복될 때까지(최대 24시간)
|
척골 신경에 15초마다 반복적인 TOF(Train-Of-Four) 전기 자극을 가하고 무지내전근에서 연축 반응을 평가하여 신경근 기능을 모니터링했습니다.
T1 및 T4는 각각 TOF 신경 자극 후 첫 번째 및 네 번째 연축의 진폭(높이)을 나타냅니다.
T4/T1 비율(최대 1.0의 십진수로 표시)은 신경근 차단(NMB)으로부터의 회복 정도를 나타냅니다.
이 연구에서는 T4/T1 비율이 >= 0.9(NMB로부터의 회복을 나타내는 최소 허용 비율)에 도달할 때까지 연축 반응을 기록했습니다.
T4/T1 비율이 0.9로 회복되는 시간이 더 빠르다는 것은 NMB에서 더 빨리 회복된다는 것을 나타냅니다.
|
1일차: 슈가마덱스 또는 위약 투여 시작부터 T4/T1 비율이 0.9로 회복될 때까지(최대 24시간)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Sugammadex 또는 위약 투여 시작부터 T4/T1 비율이 0.7로 회복되기까지의 시간
기간: 1일차: 슈가마덱스 또는 위약 투여 시작부터 T4/T1 비율이 0.7로 회복될 때까지(최대 24시간)
|
척골 신경에 반복적인 TOF 전기 자극을 15초마다 가하고 무지내전근에서 연축 반응을 평가하여 신경근 기능을 모니터링했습니다.
T1 및 T4는 각각 TOF 신경 자극 후 첫 번째 및 네 번째 연축의 진폭(높이)을 나타냅니다.
T4/T1 비율(최대 1.0의 십진수로 표시)은 NMB로부터의 회복 정도를 나타냅니다.
T4/T1 비율이 0.7로 회복하는 데 걸리는 시간이 더 빠르다는 것은 NMB에서 더 빨리 회복된다는 것을 나타냅니다.
|
1일차: 슈가마덱스 또는 위약 투여 시작부터 T4/T1 비율이 0.7로 회복될 때까지(최대 24시간)
|
Sugammadex 또는 위약 투여 시작부터 T4/T1 비율이 0.8로 회복되기까지의 시간
기간: 1일차: 슈가마덱스 또는 위약 투여 시작부터 T4/T1 비율이 0.8로 회복될 때까지(최대 24시간)
|
척골 신경에 반복적인 TOF 전기 자극을 15초마다 가하고 무지내전근에서 연축 반응을 평가하여 신경근 기능을 모니터링했습니다.
T1 및 T4는 각각 TOF 신경 자극 후 첫 번째 및 네 번째 연축의 진폭(높이)을 나타냅니다.
T4/T1 비율(최대 1.0의 십진수로 표시)은 NMB로부터의 회복 정도를 나타냅니다.
T4/T1 비율이 0.8로 회복하는 데 걸리는 시간이 더 빠르다는 것은 NMB에서 더 빨리 회복된다는 것을 나타냅니다.
|
1일차: 슈가마덱스 또는 위약 투여 시작부터 T4/T1 비율이 0.8로 회복될 때까지(최대 24시간)
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- P05971
- 19.4.208B (기타 식별자: Organon Protocol Number)
- MK-8616-035 (기타 식별자: Merck Protocol Number)
- 2005-001133-15 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
연구 데이터/문서
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Placebo에 대한 임상 시험
-
Assistance Publique - Hôpitaux de Paris아직 모집하지 않음
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로
-
AJU Pharm Co., Ltd.OM Pharma SA모병